1. Scrip
  2. >>Archive

Agile SEC filing reveals FDA rejection for Twirla contraceptive

 
• By Donna Young

Hidden deep inside a 17 March S-1 filing with the Securities and Exchange Commission (SEC) was the disclosure from Agile Therapeutics it had received a complete response letter (CRL) from the FDA for the firm's experimental once-weekly, low-dose contraceptive patch Twirla (AG200-15).

Hidden deep inside a 17 March S-1 filing with the Securities and Exchange Commission (SEC) was the disclosure from Agile Therapeutics it had received a complete response letter (CRL) from the FDA for the firm's experimental once-weekly, low-dose contraceptive patch Twirla (AG200-15).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies